glp-1 drugs for inflammation tied to lower brain inflammation, higher depression risk How Do GLP-1 Drugs Reduce

The common side effects of Mounjaro include problems with the stomach, like nausea and abdominal pain, as well as potential mood changes

For patients who want to transition from a compounded product to an FDA-approved one, both clinicians cautioned that the process isnt always straightforward, as it may not be clear what dose a patient on a compounded product had been taking

The SUMMIT trial, involving 731 individuals with HFpEF and obesity followed for a median of 104 weeks, revealed a 38% decrease in the composite endpoint of cardiovascular mortality or heart-failure deterioration events (HR: 0.62, 95%CI: 0.41-0.95, P = 0.026), driven primarily by fewer worsening heart-failure events (8.0% vs

10.1111/dom.13761 Summary Keywords anti-inflammatory, atherosclerosis, coronary artery disease, glucagon-like peptide-1, mechanisms Citation Skrobucha A, Pindlowski P, Krajewska N, Grabowski M and Jonik S (2024) Anti-inflammatory effects of glucagon-like peptide-1 (GLP-1) in coronary artery disease: a comprehensive review

[26] [27] Non-fasting samples are acceptable for routine monitoring

October 24, 2023